Q4 2024 · 13F-HR
GENERAL ATLANTIC, L.P.holdings as filed
Filed 2025-02-07 · accession 0000950142-25-000283
$2.81B
Reported value
16
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| G29018101 | DLO | DLOCAL | $719.6M | 25.6% | 63,906,695 | Common | SOLE |
| 01625V104 | ALHC | ALIGNMENT HEALTHCARE | $686.2M | 24.4% | 60,993,323 | Common | SOLE |
| 01644J108 | ALKT | ALKAMI | $353.8M | 12.6% | 9,645,318 | Common | SOLE |
| G98239109 | XP | XP, INC | $351.0M | 12.5% | 29,617,733 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS | $162.2M | 5.77% | 9,681,818 | Common | SOLE |
| 00973Y108 | AKRO | AKERO THERAPEUTICS | $145.6M | 5.18% | 5,233,989 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS | $144.4M | 5.14% | 7,531,252 | Common | SOLE |
| 29882P106 | EWCZ | EUROPEAN WAX CENTER | $87.4M | 3.11% | 13,110,492 | Common | SOLE |
| G7709Q104 | RPRX | ROYALTY PHARMA | $38.3M | 1.36% | 1,500,000 | Common | SOLE |
| 45258D105 | IMCR | IMMUNOCORE | $37.2M | 1.32% | 1,261,684 | Common | SOLE |
| 88427A107 | — | THIRD HARMONIC BIO | $34.7M | 1.24% | 3,372,323 | Common | SOLE |
| M8216R109 | RSKD | RISKIFIED | $25.2M | 0.90% | 5,324,998 | Common | SOLE |
| 00445A100 | — | ACELYRIN | $8.5M | 0.30% | 2,695,327 | Common | SOLE |
| 005329107 | ADAG | ADAGENE | $7.6M | 0.27% | 3,825,952 | Common | SOLE |
| 21077C305 | 5ZZ0 | WISH | $4.3M | 0.15% | 609,616 | Common | SOLE |
| 39957D201 | GROV | GROVE COLLABORATIVE | $3.4M | 0.12% | 2,474,859 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.